RESEARCH STATS
POOL
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
Interactions with Platform & by Email
PARTICIPANTS
Unique # Participated
VALIDATIONS
Responses Validated*
Number of executives repeatedly engaged by snail & email outreach
Interactions with Platform & by Email
Unique # Participated
Responses Validated*
*Engagement stats are ongoing and dynamic
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.
What`s New?
» Special discussions on the global economic climate and market sentiment
» Coverage on global competitiveness and key competitor percentage market shares
» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass™ research platform
» Complimentary updates for one year
» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes
Economic Outlook
The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.
The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.
Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Bleeding Disorders Treatment Market to Reach $22 Billion by 2030
The global market for Bleeding Disorders Treatment estimated at US$14.6 Billion in the year 2022, is projected to reach a revised size of US$22 Billion by 2030, growing at aCAGR of 5.2% over the period 2022-2030. Hemophilia A, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$12.3 Billion by the end of the analysis period. Growth in the Hemophilia B segment is estimated at 5.6% CAGR for the next 8-year period.
The U.S. Market is Estimated at $4 Billion, While China is Forecast to Grow at 8.6% CAGR
The Bleeding Disorders Treatment market in the U.S. is estimated at US$4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.8% and 5.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.
Bayer AG; CSL Behring; Grifols International SA; Novo Nordisk A/S; Octapharma AG; Pfizer, Inc.
» Type (Hemophilia A, Hemophilia B, Other Types) » Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants, Other Drug Classes)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Bleeding Disorders Treatment to Witness Steady Growth |
Hemophilia A to Account for Highest Growth |
Table: Total Number of People Worldwide with Bleeding Disorders by Condition: 2017 |
Recombinant Coagulation Factor Concentrates to Register Largest Market Share |
Table: Total Recombinant Coagulation Factors Sales of Novo Nordisk |
Bleeding Disorders Treatment – Global Key Competitors Percentage Market Share in 2022 (E) |
Bleeding Disorders Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
A Prelude into Hemophilia Product Sales of Leading Players |
Table: Hemophilia Product Portfolio of Leading Players |
Table: Total Sales of Hemophilia Drugs by Leading Players-2017 |
Table: Annual Hemophilia Product Sales of Shire in Billion USD for the years 2015, 2016, and 2017 |
Table: Market Share of Novo Nordisk in Haemophilia: 2017 |
Table: Total Sales for Novo Nordisk in Haemophilia Segment: 2018 |
Select Products in Developmental Stage |
Select Mergers and Acquisitions |
3. MARKET TRENDS & DRIVERS |
Increasing Prevalence of Bleeding Disorders to Propel Market Prospects |
Table: Total Number of Patients with Bleeding Disorders for Select Countries: 1999 to 2017 |
Table: Total Number Patients with Haemophilia A and Haemophilia B |
Prophylactic Treatment in Hemophilia to Support Market Growth |
Table: Percentage Breakdown of Diagnosis and Treatment Rates in Haemophilia |
Emerging Therapies/ Investments to Spur Market Demand |
New Product Launches/ Approvals to Support Market Growth |
Higher Cost of Drugs to Hinder Bleeding Disorders Treatment |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Bleeding Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Hemophilia A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Plasma-derived Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Plasma-derived Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Plasma-derived Coagulation Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Recombinant Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Recombinant Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Recombinant Coagulation Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Fibrin Sealants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Fibrin Sealants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Fibrin Sealants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Bleeding Disorders Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
USA Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
CANADA |
Table: Percentage Breakdown of Total Population in Canada with Hemophilia by Age Group: 2017 |
Canada Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Canada Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
JAPAN |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Japan Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
CHINA |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
China Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
China Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
EUROPE |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
Europe Historic Review for Bleeding Disorders Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
FRANCE |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
France Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
France Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
GERMANY |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Germany Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Italy Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
UNITED KINGDOM |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
UK Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Spain Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Spain 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Spain Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Spain Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Spain 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Russia Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Russia 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Russia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Russia Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Russia 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
ASIA-PACIFIC |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Bleeding Disorders Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
AUSTRALIA |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E) |
Australia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Australia Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Australia 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Australia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Australia Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Australia 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
INDIA |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E) |
India Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
India Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
India 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
India Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
India Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
India 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
South Korea Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
South Korea 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
South Korea Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
South Korea Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
South Korea 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
LATIN AMERICA |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E) |
Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Bleeding Disorders Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030 |
Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
ARGENTINA |
Argentina Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Argentina Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Argentina 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Argentina Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Argentina Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Argentina 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
BRAZIL |
Brazil Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Brazil Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Brazil 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Brazil Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Brazil Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Brazil 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
MEXICO |
Mexico Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Mexico Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Mexico 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Mexico Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Mexico Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Mexico 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
REST OF LATIN AMERICA |
Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Latin America Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Latin America 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Latin America Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Latin America 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
MIDDLE EAST |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E) |
Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Bleeding Disorders Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030 |
Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
IRAN |
Iran Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Iran Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Iran 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Iran Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Iran Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Iran 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
ISRAEL |
Israel Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Israel Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Israel 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Israel Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Israel Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Israel 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
SAUDI ARABIA |
Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Saudi Arabia Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Saudi Arabia 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Saudi Arabia Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Saudi Arabia 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
UNITED ARAB EMIRATES |
UAE Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UAE Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UAE 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
UAE Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
UAE Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
UAE 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
REST OF MIDDLE EAST |
Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Middle East Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Middle East 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Rest of Middle East Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Rest of Middle East 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
AFRICA |
Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E) |
Africa Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Africa Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Africa 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030 |
Africa Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR |
Africa Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR |
Africa 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030 |
IV. COMPETITION |
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com
Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .
What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).
Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.
Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.
Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.
Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.
Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.
Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.
Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.